NVO [NYSE]
Novo Nordisk A/S
Index- P/E34.61 EPS (ttm)3.03 Insider Own26.40% Shs Outstand2.27B Perf Week-2.51%
Market Cap184.65B Forward P/E3.67 EPS next Y28.56 Insider Trans0.00% Shs Float1.08B Perf Month-9.51%
Income6.94B PEG17.39 EPS next Q6.01 Inst Own8.30% Short Float0.12% Perf Quarter-1.44%
Sales21.60B P/S8.55 EPS this Y15.20% Inst Trans0.11% Short Ratio0.88 Perf Half Y3.40%
Book/sh4.51 P/B23.24 EPS next Y20.03% ROA25.80% Target Price128.20 Perf Year-0.11%
Cash/sh2.42 P/C43.31 EPS next 5Y1.99% ROE72.80% 52W Range91.51 - 122.16 Perf YTD-6.42%
Dividend1.61 P/FCF38.24 EPS past 5Y6.70% ROI48.60% 52W High-16.18% Beta0.45
Dividend %1.53% Quick Ratio0.70 Sales past 5Y4.70% Gross Margin83.90% 52W Low11.90% ATR3.01
Employees50816 Current Ratio0.90 Sales Q/Q24.90% Oper. Margin42.20% RSI (14)37.82 Volatility1.68% 2.51%
OptionableYes Debt/Eq0.34 EPS Q/Q11.30% Profit Margin32.10% Rel Volume0.83 Prev Close104.81
ShortableYes LT Debt/Eq0.32 EarningsAug 03 BMO Payout357.20% Avg Volume1.48M Price102.40
Recom1.30 SMA20-6.80% SMA50-7.08% SMA200-5.53% Volume782,443 Change-2.30%
Jul-15-22Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-28-22Downgrade UBS Neutral → Sell
Jun-27-22Upgrade Exane BNP Paribas Underperform → Neutral
Jun-07-22Upgrade JP Morgan Neutral → Overweight
May-31-22Upgrade Guggenheim Neutral → Buy
Apr-25-22Upgrade Cowen Market Perform → Outperform $130
Apr-12-22Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-16-22Upgrade Deutsche Bank Hold → Buy
Jan-25-22Downgrade Liberum Hold → Sell
Dec-20-21Downgrade JP Morgan Overweight → Neutral
Dec-17-21Downgrade Deutsche Bank Buy → Hold
Jan-20-21Downgrade Credit Suisse Outperform → Neutral
Jan-15-21Initiated Deutsche Bank Buy
Sep-29-20Initiated Berenberg Hold
Jul-06-20Downgrade BofA Securities Buy → Neutral
May-11-20Downgrade UBS Buy → Neutral
May-04-20Initiated Cowen Market Perform $72
Mar-16-20Upgrade BofA/Merrill Neutral → Buy
Jan-03-20Downgrade Guggenheim Buy → Neutral
Nov-18-19Upgrade Barclays Equal Weight → Overweight
Aug-17-22 11:56PM  
10:00AM  
Aug-15-22 08:19AM  
Aug-14-22 11:09AM  
Aug-13-22 06:11AM  
Aug-12-22 09:10PM  
Aug-09-22 10:37AM  
Aug-08-22 11:06AM  
Aug-05-22 11:13AM  
09:32AM  
05:30AM  
Aug-04-22 03:01PM  
12:26PM  
10:00AM  
05:40AM  
Aug-03-22 04:01PM  
02:01PM  
10:39AM  
10:36AM  
10:21AM  
09:48AM  
05:43AM  
Aug-01-22 12:07PM  
10:08AM  
Jul-31-22 07:00AM  
Jul-29-22 01:42PM  
07:43AM  
Jul-25-22 07:04AM  
Jul-23-22 12:15PM  
Jul-22-22 11:30AM  
Jul-19-22 06:40AM  
Jul-18-22 05:39PM  
06:34AM  
Jul-15-22 11:43AM  
Jul-14-22 11:07AM  
09:11AM  
12:00AM  
Jul-12-22 11:13AM  
09:54AM  
Jul-11-22 02:23PM  
01:24PM  
12:52PM  
11:45AM  
09:45AM  
06:41AM  
Jul-10-22 10:02AM  
Jul-08-22 11:44AM  
11:31AM  
11:14AM  
Jul-07-22 11:58AM  
11:34AM  
Jul-06-22 01:15PM  
01:04PM  
09:15AM  
09:13AM  
09:03AM  
08:00AM  
Jul-05-22 12:56PM  
12:13PM  
10:16AM  
10:00AM  
07:51AM  
Jul-04-22 12:45PM  
12:25PM  
10:34AM  
08:54AM  
Jul-02-22 11:15AM  
Jul-01-22 11:45AM  
11:03AM  
10:33AM  
10:00AM  
Jun-30-22 10:20AM  
Jun-29-22 12:41PM  
12:39PM  
09:23AM  
09:17AM  
Jun-28-22 01:08PM  
01:06PM  
12:15PM  
10:14AM  
Jun-27-22 12:38PM  
11:55AM  
11:08AM  
11:01AM  
09:02AM  
07:29AM  
Jun-24-22 10:16AM  
Jun-23-22 08:00AM  
Jun-20-22 08:44AM  
Jun-17-22 12:45PM  
Jun-15-22 08:25AM  
Jun-13-22 09:00AM  
Jun-12-22 12:31PM  
Jun-11-22 09:42AM  
Jun-10-22 06:26PM  
09:36AM  
09:05AM  
08:00AM  
Jun-09-22 11:41AM  
08:30AM  
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.